WHAT IS CLAIMED IS:

1. A composition comprising a polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide and a lipid associated with said polynucleotide.

2. The composition of claim 1, wherein said polynucleotide is an oligonucleotide having a length of between about 8 and about 50 bases.

3. The composition of claim 1, wherein the polynucleotide hybridizes to the translation initiation site of Bcl-2 mRNA.

4. The composition of claim 3, wherein the polynucleotide is an oligonucleotide comprising the sequence CAGCGTGCGCCATCCTTC (SEQ ID NO:1).

5. The composition of claim 1, comprising a liposome formed from the lipid.

6. The composition of claim 5, wherein the polynucleotide is encapsulated in the liposome.

7. The composition of claim 1, wherein the lipid is a phosphatidylcholine, a phosphatidylglycerol, or a phosphatidylethanolamine.

8. The composition of claim 7, wherein the lipid is dioleoylphosphatidylcholine.

9. A composition comprising an expression construct that encodes a first polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide, wherein said first polynucleotide is under the control of a promoter that is active in eukaryotic cells.

10. A method of inhibiting a Bcl-2-associated disease comprising obtaining a polynucleotide that hybridizes to a Bcl-2-encoding polynucleotide, mixing the polynucleotide with a lipid to form a polynucleotide/lipid association, and administering said association to a cell.

11. The method of claim 10, wherein the cell is a cancer cell.

12. The method of claim 11, wherein said cancer cell is a follicular lymphoma cell.

13. The method of claim 10, wherein said polynucleotide is an oligonucleotide having a length of between about 8 and about 50 bases.

14. The method of claim 10, comprising a liposome formed from the lipid.

15. The method of claim 14, wherein the liposome encapsulates the polynucleotide.

16. The method of claim 10, wherein said contacting takes place in an animal.

17. The method of claim 16, wherein said animal is a human.

18. The method of claim 17, wherein said composition is delivered to said human in a volume of 0.50-10.0 ml per dose.

19. The method of claim 17, wherein said composition is delivered to said human in an amount of from about 5 to about 30 mg polynucleotide per m^2.

20. The method of claim 19, wherein said composition is administered three times per week for eight weeks.

ADD G4